{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:43:43Z","timestamp":1785833023733,"version":"3.56.0"},"reference-count":59,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CMAR"],"DOI":"10.2147\/cmar.s227583","type":"journal-article","created":{"date-parts":[[2020,7,12]],"date-time":"2020-07-12T20:53:00Z","timestamp":1594587180000},"page":"5667-5676","source":"Crossref","is-referenced-by-count":28,"title":["<p>Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer<\/p>"],"prefix":"10.2147","volume":"Volume 12","author":[{"given":"E David","family":"Crawford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4134-7495","authenticated-orcid":true,"given":"Whitney","family":"Stanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divneet","family":"Mandair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"key":"ref2","unstructured":"American Cancer Society. Cancer Facts & Figures 2020. Atlanta: American Cancer Society; 2020. Available from https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2020\/cancer-facts-and-figures-2020.pdf.Accessed January 27, 2020."},{"key":"ref3","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer version 1.2020. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed May 20, 2020."},{"key":"ref4","unstructured":"Mottet N, van den Bergh RCN, Briars E, et al. Prostate cancer guidelines 2019. Available from: https:\/\/uroweb.org\/guideline\/prostate-cancer\/. Accessed January 27, 2020."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fendo.2017.00187","volume":"8","author":"Gr\u00fcndker","year":"2017","journal-title":"Front Endocrinol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.juro.2018.07.090","volume":"200","author":"Lowrance","year":"2018","journal-title":"J Urol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.eururo.2014.09.049","volume":"67","author":"Karantanos","year":"2015","journal-title":"Eur Urol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.juro.2018.04.083","volume":"200","author":"Crawford","year":"2018","journal-title":"J Urol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref12","first-page":"5","author":"Hess-Busch","year":"2019","journal-title":"World J Urol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.clgc.2018.07.017","volume":"16","author":"Fizazi","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.ijrobp.2019.03.014","volume":"104","author":"McCarthy","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3389\/fonc.2019.00801","volume":"9","author":"Rice","year":"2019","journal-title":"Front Oncol"},{"key":"ref16","first-page":"13","author":"El-Amm","year":"2019","journal-title":"Clin Med Insights Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1210\/mend.9.2.7776971","volume":"9","author":"Zhou","year":"1995","journal-title":"Mol Endocrinol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.1210\/endo.140.10.7039","volume":"140","author":"Wright","year":"1999","journal-title":"Endocrinology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"8253","DOI":"10.1200\/JCO.2005.03.4777","volume":"23","author":"Scher","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","volume":"360","author":"Andriole","year":"2009","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0094-0143(21)01398-7","volume":"18","author":"Goldenberg","year":"1991","journal-title":"Urol Clin North Am"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Group PCTC. Prostate Cancer Trialists\u2019 Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355(9214):1491\u20131498. doi:10.1016\/S0140-6736(00)02163-2","DOI":"10.1016\/S0140-6736(00)02163-2"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000473717","volume":"29","author":"Thorpe","year":"1996","journal-title":"Eur Urol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/cancers12010051","volume":"12","author":"Saranyutanon","year":"2019","journal-title":"Cancers"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0022-4731(88)90206-3","volume":"31","author":"Plante","year":"1988","journal-title":"J Steroid Biochem"},{"key":"ref26","first-page":"145","volume":"243A","author":"Labrie","year":"1987","journal-title":"Prog Clin Biol Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1586\/eem.11.33","volume":"6","author":"Knudsen","year":"2011","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/sj.bjc.6690684","volume":"81","author":"Culig","year":"1999","journal-title":"Br J Cancer"},{"key":"ref29","first-page":"149","volume":"63","author":"Hara","year":"2003","journal-title":"Cancer Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"12007","DOI":"10.1038\/srep12007","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci Rep"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1586\/14737140.2015.1081566","volume":"15","author":"Fizazi","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1200\/JCO.2018.36.6_suppl.345","volume":"36","author":"Zurth","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1200\/JCO.2019.37.7_suppl.156","volume":"37","author":"Zurth","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.euf.2017.01.010","volume":"3","author":"Fizazi","year":"2017","journal-title":"Eur Urol Focus"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/jco.2014.32.4_suppl.115","volume":"32","author":"Massard","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.eururo.2015.09.046","volume":"69","author":"Massard","year":"2016","journal-title":"Eur Urol"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Fizazi K, Shore ND, Tammela T, et al. Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol. 2020;38(15):(suppl; abstr 5514). doi:10.1200\/JCO.2020.38.15_suppl.5514. Published online May 25, 2020.","DOI":"10.1200\/JCO.2020.38.15_suppl.5514"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"8769","DOI":"10.2147\/OTT.S197244","volume":"12","author":"Bastos","year":"2019","journal-title":"OncoTargets Ther"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/S1470-2045(13)70424-8","volume":"14","author":"Basch","year":"2013","journal-title":"Lancet Oncol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/annonc\/mds585","volume":"24","author":"Sternberg","year":"2013","journal-title":"Ann Oncol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","volume":"375","author":"Scher","year":"2010","journal-title":"Lancet"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.euf.2017.01.015","volume":"4","author":"Shore","year":"2018","journal-title":"Eur Urol Focus"},{"key":"ref46","author":"Roviello","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e871","DOI":"10.1016\/j.clgc.2019.07.001","volume":"17","author":"Di Nunno","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"ref48","unstructured":"U.S. Food and Drug Administration. FDA drug safety communication: update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases. FDA. June 2019. Available from: http:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-update-ongoing-safety-review-gnrh-agonists-and-notification. Accessed January 29, 2020."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","volume":"33","author":"O\u2019Farrell","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1021\/jm00013a022","volume":"38","author":"Potter","year":"1995","journal-title":"J Med Chem"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/j.1464-410X.2005.05821.x","volume":"96","author":"Attard","year":"2005","journal-title":"BJU Int"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.juro.2018.03.125","volume":"200","author":"Ryan","year":"2018","journal-title":"J Urol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","volume":"16","author":"Iacovelli","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s13318-019-00577-5","volume":"44","author":"Zurth","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","volume":"14","author":"Shore","year":"2019","journal-title":"Target Oncol"},{"key":"ref58","unstructured":"Nubeqa\u00ae (Darolutamide) [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc; 2019."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.eururo.2018.07.035","volume":"75","author":"Mateo","year":"2019","journal-title":"Eur Urol"}],"container-title":["Cancer Management and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=59652","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=59652","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T12:14:23Z","timestamp":1667391263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/darolutamide-an-evidenced-based-review-of-its-efficacy-and-safety-in-t-peer-reviewed-article-CMAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":59,"URL":"https:\/\/doi.org\/10.2147\/cmar.s227583","relation":{},"ISSN":["1179-1322"],"issn-type":[{"value":"1179-1322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}